APSR2026-201

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP12-005
P82
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1213504-46904-#APSR2026-201_AP12-005_439196.pdf
Format: PDF Only
16. Interstitial Lung Disease
1

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jae Ha Lee * Inje University, Haeundae Paik Hospital Pulmonology Busan Korea, ROK (South)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Jae Ha
Lee
anilleus@naver.com
+821064175936
41-50
 
Original Research
Nationwide Incidence and Prevalence of Idiopathic Pulmonary Fibrosis in South Korea
Maximum 25 words
Abstract Content
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality. Population-based data on long-term epidemiological trends and real-world treatment outcomes in Asia remain limited. This study described national trends in IPF prevalence and incidence in South Korea and evaluated pirfenidone use and associated mortality.
Using the Korean National Health Insurance Service customized research database, we identified prevalent IPF cases from 2010 to 2023 and incident cases from 2011 to 2023. IPF was defined using the International Classification of Diseases, 10th Revision, and rare incurable disease codes, applying broad and strict operational definitions. Among patients meeting the broad definition, the association between pirfenidone use and all-cause mortality was assessed using multivariable-adjusted Cox proportional hazards models.
Under the broad definition, 114,146 prevalent and 35,517 incident IPF cases were identified; under the strict definition, 91,638 prevalent and 28,683 incident cases were identified. IPF prevalence increased steadily over time, reaching 34.27 per 100,000 population in 2023 under the broad definition, with similar trends observed under the strict definition. Incidence also increased, particularly among older adults. IPF was more common in men, and demonstrated a pronounced age gradient. Following reimbursement approval, pirfenidone use increased substantially. Pirfenidone use was associated with a reduced risk of all-cause mortality (adjusted hazard ratio, 0.640; 95% confidence interval, 0.616–0.665), with progressively stronger associations observed with longer treatment duration.
The burden of IPF in South Korea has increased over the past decade, during which expanded real-world pirfenidone use was associated with improved survival.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1213504-37089-fig1_372467.jpg
JPG or JPEG or PNG format ONLY
Pulmonary Fibrosis; Idiopathic; Epidemiology; Incidence; Prevalence; Pirfenidone
maximum 3 keywords and no abbreviations, separated by commas
On behalf of Korea ILD Study Group
255